The presented study identified a novel apoptotic pathway, involving the ubiquitin-proteasomal degradation of the anti-apoptotic protein HAX1 by the previously orphan SCFFBXO25 E3 ubiquitin ligase. This process is controlled in a spatiotemporal manner by the pro-apoptotic kinase PRKCD. Several in vivo studies and analyses of human patient material identified the disruption of the PRKCD-FBXO25-HAX1 as an essential mechanism for cell migration, lymphomagenesis, and treatment resistance in B-cell lymphoma, thus underlining HAX1 as novel therapeutic target structure in B-NHL.
«
The presented study identified a novel apoptotic pathway, involving the ubiquitin-proteasomal degradation of the anti-apoptotic protein HAX1 by the previously orphan SCFFBXO25 E3 ubiquitin ligase. This process is controlled in a spatiotemporal manner by the pro-apoptotic kinase PRKCD. Several in vivo studies and analyses of human patient material identified the disruption of the PRKCD-FBXO25-HAX1 as an essential mechanism for cell migration, lymphomagenesis, and treatment resistance in B-cell ly...
»